Swedish Orphan Biovitrum
293.6
SEK
-0.47 %
Less than 1K followers
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-0.47%
+5.76%
-5.72%
-7.5%
-4.61%
+6.3%
+46.09%
+54.38%
+515.27%
Swedish Orphan Biovitrum operates in the pharmaceutical industry and focuses on the development and distribution of medicines for rare diseases. The company's products are aimed at healthcare institutions and patients with specific medical needs. The business is global with a main presence in Europe, North America and Asia. Swedish Orphan Biovitrum was founded in 1939 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
104.52B SEK
Turnover
33.02M SEK
Revenue
26.03B
EBIT %
21.61 %
P/E
25.82
Dividend yield-%
-
Financial calendar
15/7
2025
Interim report Q2'25
23/10
2025
Interim report Q3'25
All
Press releases
ShowingAll content types
Swedish Orphan Biovitrum AB: Kommuniké från Sobis årsstämma
Swedish Orphan Biovitrum AB: Sobi publishes Q1 2025 report: Portfolio continues to deliver
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools